Nya antivirala läkemedel mot hepatit C i kliniska studier. Ger hopp om bot - men resistensproblematiken måste bemästras
Engelsk titel: New antiviral agents against hepatitis C in clinical trials. Hope for a cure - but resistance problems must be overcomed
Läs online
Författare:
Lennerstrand J
;
Bondeson K
;
Bergqvist A
;
Blomberg J
;
Öberg B
Email: johan.lennerstrand@medsci.uu.se
Språk: Swe
Antal referenser: 34
Dokumenttyp:
Översikt
UI-nummer: 09121030
Sammanfattning
The current global infection rate for Hepatitis C virus (HCV) is 170 million, while approximately 45 000 people are chronic carriers of the virus in Sweden. The HCV is considered to be the leading cause of liver cirrhosis and liver cancer. Although considerable progress has been made in the treatment of HCV, current interferon/ribavirin based regimens have an approximate 50% success rate in the Western world and incur considerable side effects. New antiviral agents that inhibit HCV enzymes are now in an advanced stage of clinical development. Even so, the success of these specifically targeted antiviral therapies for HCV (STAT-C) may be limited due to the appearance of drug resistance in ongoing clinical trails. Furthermore, a combination therapy containing STAT-C and current treatment will most likely be required to treat HCV infection. Additionally, due to the extremely high sequence diversity of HCV, natural pre-existing drug resistance mutations have been found in treatment naïve patients. This review discusses the future problems that could occur with drug resistance to STAT-C. Consequently, detection of resistance mutations is expected to be a part of the HCV routine diagnostics.